THE ALVIN AND LOIS LAPIDUS CANCER INSTITUTE
ONCOLOGY PROTOCOL REFERENCE
May 2006

Bladder Cancer

GCC 0318 : A Phase II Study of Doxorubicin/Taxotere (DT) Followed by Gemcitabine/Cisplatin (GC) in Patients with Locally Advanced/ Metastatic Cancer of the Bladder/Urothelium

NSABP B-35 : A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy

NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cytoxan (FEC) To Four Cycles of Adriamycin and Cytoxan (AC) In Patients With Node Negative Breast Cancer.

NSABP B-38:- A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node- Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC- P); DD AC Followed by DD Paclitaxel plus Gemcitabine (DD ACPG)".

NCIC CTG: MA.27-"A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer.

Genentech H2757n-RegistHER : An Observational Cohort Study of Patients with HER-@ Positive Metastatic Breast Cancer

Colon/Colorectal Cancer 

NSABP C-08:  A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil(5-FU), Leucovorin, and Oxaliplatin(mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for Treatment of Patients with Resected Stages II and III Carcinoma of the Colon

Amgen 20040249 - A Randomized ,Open-label, Controlled, Clinical Trail of chemotherapy and Bevacizumab With or Without Panitumumab in the First -Line Treatment of Subjects with Metastatic Colorectal C

ACOSOG Z9001: A Phase III Randomized Double-blind Study of Adjuvant STI571 (GleevecTM) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST)

D0410: Dartmouth -Hitchcock Medical Center- " A National Web-Based Randomized Phase III Study of Erlotinib or Placebo following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer"

OSI3364g:A Phase III, Multicenter, Placebo- Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva( Erlotinib) Compared with Tarceva Alone for treatment of Advanced Non-Small Cell Lung Cancer After Failure of Standard First Line Chemotherapy.

S9925:Lung Cancer Specimen Repository Protocol, Ancillary

UPCI 04-094 - A Randomized, phase III trial of adjuvant versus neo-adjuvant chemotherapy with cisplatin and docetaxel for patients with early stage non-small cell lung cancer.

S0016: A Phase III Trial of CHOP + Rituximab versus CHOP + Iodine �131- Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin�s Lymphomas

E4402: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Reginmens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

U2963n: The National Lymphocare STudy: An observational study of treatment, outcomes and prognosis in patients with follicular Non-Hodgkin's Lymphoma

LY-01-2006:   A Phase II Dose Study of Doxil� in A Dose -Dense, 14 Day CDOP/Rituximab Regimen for Patients with Diffuse Large B-Cell NHL > 60 years or with Compromised Cardiac Status

SP P02978: A Pivotal Randomized Phase III Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia

SWOG-9007: Cytogenetic Studies in Leukemia Patients

SWOG 9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary

SWOG E4697 : A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with No Evidence of Disease� after Complete  Surgical Resection of Locally Advanced� and/or Stage IV Melanoma

SWOG 0008 : Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma

SWOG E1697 :  Phase III Randomized Study of Four Weeks High Dose IFN-?2b in Stage T3-T4 or N1 (Microscopic) Melanoma

P01-02-17: Phase III Study of Taxoprexin (DHA-paclitaxel) Injection vs. Dacarbazine, DTIC Plus IL-2 adn Interferon in Patients wiht HIgh Risk Melanoma

26866138-MMY-3002:" An Open-Label, Randomized Study of Velcade/Melphalan/Prednisone versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma

Celgene- An Evaluation of Thalidomide and Oral VP-16 as Salvage Therapy for Surgical Stage 3 or 4 Epithelial Ovarian and Primary Peritoneal Carcinomas

GSK: Phase II Evaluation of Weekly Hycamtin in Recurrent Platinum Sensitive and Platinum-Resistant/Refractory Ovarian Cancer

TLK286.3024:A Phase III Randomized Study of TLK286 in combination with Carboplatin versus Liposomal Doxorubicin as Second Line Therapy in Platinum Refractory or Resistant Ovarian Cancer

GCC 0162 : A Phase I/II STudy of WEekly Doxorubicin and Taxotere, Followed by Total Androgen Suppression (TAS) in Patients who Experience Biochemical Failure after Prostatectomy and/or Radiation for Localized/locally

GCC 9983 : A Phase I/II Study of Weekly Doxorubicin and Taxotere for the Treatment of Patients with Hormone Refractory Prostate Cancer

SWOG 0344: Phase II Surgical Trial of Intralesional Resection of Low-grade Intracompartmental Chondrosarcoma of Bone

Supportive Care

HA006- Phase 3, Multicenter, Multi- National, Randomized, Double Blind Placebo -controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Occluded Central Venous Access Devices.

The Alvin and Lois Lapidus Cancer Institute
2401 West Belvedere Avenue
Baltimore, Maryland 21215
Phone: 410- 601- 6120
Fax: 410- 601- 4714

Oncology Research Team:

Judy Bosley, BSN, RN          Clinical Research Nurse Manager
Lynn Crawford, BSN, RN     Clinical Research Nurse
Pam Nickoles, BSN, RN       Clinical Research Nurse
Jennifer Hertsch, BS               Research Associate
Yana Rachinskaya, MS          Clinical Research Program Coordinator